CNBCBiogen stock falls after FDA calls for federal investigation into Alzheimer's drug approvalJul 9, 2021more_vert
The Wall Street JournalBiogen Alzheimer's Drug Will Exceed the $56000 List Price for Many, Analysis SaysJul 9, 2021Joseph WalkerBy Joseph Walkermore_vert
STATAduhelm's accelerated approval offers a promising roadmap for rare neurological diseasesJul 7, 2021Emil KakkisBy Emil Kakkismore_vert
The Washington PostFDA head urges probe of agency's dealings with Biogen, maker of controversial new Alzheimer's drugJul 9, 2021Laurie McGinleyBy Laurie McGinleymore_vert
The New York TimesA New Alzheimer's Drug Offers More Questions Than Answers (Published 2021)Sep 2, 2021Paula SpanBy Paula Spanmore_vert
FiercePharmaBiogen, FDA walk back controversial Aduhelm label after weeks of fierce criticismJul 8, 2021Noah Higgins-DunnBy Noah Higgins-Dunnmore_vert
The Washington PostThe controversial approval of an Alzheimer's drug reignites the battle over the underlying cause of the diseaseJul 5, 2021Laurie McGinleyBy Laurie McGinleymore_vert